Live

China retaliated with 34% tariffs on US goods, while Trump vows his policies will 'never change.'

LSE - Delayed Quote GBp

Renalytix Plc (RENX.L)

8.00

-0.50

(-5.88%)

As of 12:28:02 PM GMT+1. Market Open.

Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal quarter of 2025 ended September 30, 2024.

PR Newswire 4 months ago

RNLXY

RTNXF
Commencement of trading on OTCQB in the United States

Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intentio

GlobeNewswire 5 months ago

RNLX

RTNXF
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno’), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus

GlobeNewswire 8 months ago

RNLX

RTNXF
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearing

GlobeNewswire 9 months ago

RNLX

RTNXF
Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance CoverageLONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's kidneyintelX.dkd testing. The final LCD can be accessed at LCD - KidneyIntelX and KidneyIntelX.dkd Testing (L39726) (cms.g

GlobeNewswire 9 months ago

RNLX

RTNXF
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of

GlobeNewswire 10 months ago

RNLX

RTNXF
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference

GlobeNewswire 10 months ago

RNLX

RTNXF
Renalytix Announces Financing with Expected Size of up to $4 Million

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas

GlobeNewswire 11 months ago

RNLX

RTNXF

Performance Overview

Return	RENX.L	FTSE 100 (^FTSE)
YTD	-25.58%	-0.25%
1-Year	-71.43%	+2.22%
3-Year	-97.14%	+7.85%

Try again.